Hypertrophic Obstructive Cardiomyopathy Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Myocardial perfusion improvement and mechanism after percutaneous intramyocardial septal radiofrequency ablation in obstructive hypertrophic cardiomyopathy: a study of myocardial contrast echocardiography
AbstractThe data on myocardial perfusion of the percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) for obstructive hypertrophic cardiomyopathy (HOCM) are still lacking, although PIMSRA have been proved to be of great safety and efficacy. The aim of this study was to quantitatively analyze the changes in myocardial perfusion after PIMSRA using myocardial contrast echocardiography (MCE). 27 HOCM patients treated with PIMSRA were retrospectively analyzed, and their echocardiographic parameters and perfusion parameters of MCE were collected before and 12 months after PIMSRA. A reperfusion curve was used to qu...
Source: The International Journal of Cardiovascular Imaging - May 6, 2024 Category: Radiology Source Type: research

Transapical intramyocardial septal microwave ablation in treatment of hypertrophic obstructive cardiomyopathy: 12-month outcomes of a swine model
To date, the extended Morrow procedure is considered the gold standard treatment for patients with obstructive hypertrophic cardiomyopathy who experience severe symptoms and are unresponsive to medication trea... (Source: Journal of Cardiothoracic Surgery)
Source: Journal of Cardiothoracic Surgery - April 13, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Mi Zhou, Zhaolong Li, Yun Liu, Yuehua Fang, Le Qin, Wenjie Yang, Fuhua Yan and Qiang Zhao Tags: Research Source Type: research

Novel Therapies for the Treatment of Cardiovascular Disease
Over the last decade, randomized clinical trials of several pharmacologic agents have demonstrated a reduction in cardiovascular mortality and other important secondary outcomes. Angiotensin-Neprilysin Inhibitors and Sodium-Glucose Co-transporter 2 inhibitors have now become pillars in the treatment of heart failure. Ivabradine is a negative chronotropic agent used as an adjunctive therapy in patients with heart failure. Two new hypertension therapies, zilebresiran and aprocitentan, are currently in investigational stages. Finally, mavacamten has emerged as a pharmacologic treatment for hypertrophic obstructive cardiomyopa...
Source: Medical Clinics of North America - April 12, 2024 Category: Primary Care Authors: Abdul Aziz A. Asbeutah, Zachary D. Goldberger Source Type: research

Left Ventricle Assist Device as a Treatment for Burned Out Hypertrophic Obstructive Cardiomyopathy
Introduction: LVAD is a promising treatment for severe burned-out hypertrophic obstructive cardiomyopathy(HOCM)with refractory HF (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: R. Sadraldin, , A. Alkhaldi, M. Bin Hudhud Source Type: research

Predictive value of estimated plasma volume for postoperative hypotension in percutaneous intramyocardial septal radiofrequency ablation treating for hypertrophic obstructive cardiomyopathy
Estimated plasma volume status (ePVS) estimated by the Duarte formula is associated with clinical outcomes in patients with heart failure. It remains unclear the predictive value of the ePVS to the postoperati... (Source: BMC Cardiovascular Disorders)
Source: BMC Cardiovascular Disorders - March 22, 2024 Category: Cardiology Authors: Bo Shan, Jing Li, Zhangwei Shi, Chao Han, Juan Zhang, Jia Zhao, Rui Hu, Liwen Liu and Shengjun Ta Tags: Research Source Type: research

A case of hypertrophic cardiomyopathy with previous aortic valve replacement
We describe a 45-year-old patient who was diagnosed with hypertrophic obstructive cardiomyopathy (HOCM) after the aortic valve replacement surgery. Enlarged left atria, thickened ventricular septum, left ventr... (Source: Journal of Cardiothoracic Surgery)
Source: Journal of Cardiothoracic Surgery - March 19, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Hongyan Xiao, Laichun Song, Meng Guo and Liang Tao Tags: Case Report Source Type: research

Remimazolam-based anesthesia in a patient with hypertrophic obstructive cardiomyopathy undergoing radical colorectal cancer surgery: A case report
CONCLUSION: In this patient with HOCM, remimazolam and remifentanil provided adequate anesthesia for induction and maintenance to complete the right hemicolectomy.PMID:38428902 | DOI:10.1097/MD.0000000000037199 (Source: Cancer Control)
Source: Cancer Control - March 1, 2024 Category: Cancer & Oncology Authors: Yongchang Shi Chengchao Zuo Yiwen Zhang Chao Zhou Fengjiao Zhang Xuelian Zhao Source Type: research

Is There a Role for Alcohol Septal Ablation in Young Patients with Medically Refractory Hypertrophic Obstructive Cardiomyopathy?
AbstractSurgical myectomy is recommended for symptomatic hypertrophic obstructive cardiomyopathy (HOCM) after optimal pharmacological therapy. Percutaneous transluminal septal myocardial ablation (PTSMA) is reserved for high-risk adults. Symptomatic patients below 25 years underwent either surgery or PTSMA after heart-team discussion and informed consent. Echocardiography assessed gradients in surgical group. PTSMA group underwent invasive transseptal hemodynamic assessment, selective coronary angiography and super-selective cannulation of septal perforators u sing microcatheters. Contrast echocardiography through the mi...
Source: Pediatric Cardiology - February 28, 2024 Category: Cardiology Source Type: research

Withdrawal Of Atrioventricular Nodal Blocking Agents in Patients Receiving Mavacamten: A Retrospective Single-Center Experience in A Predominantly Asian-American Cohort
Hypertrophic obstructive cardiomyopathy (HOCM) is a hereditary condition in which cardiac muscle progressively hypertrophies, leading to hypercontractility, impaired relaxation, and blockage of the left ventricular outflow tract (LVOT).1 Mavacamten is a recently approved medication that inhibits myosin activation, improving quality of life, functional status, and cardiac function.2 –6 (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 27, 2024 Category: Cardiology Authors: Kevin Benavente, Jesus Pino Moreno, Dipanjan Banerjee Tags: Brief Report Source Type: research

Evolving indications for transcatheter mitral edge-to-edge repair
EuroIntervention. 2024 Feb 19;20(4):e230-e238. doi: 10.4244/EIJ-D-23-00700.ABSTRACTTranscatheter mitral edge-to-edge repair (TEER) is an established procedure for managing mitral regurgitation (MR) in high-risk patients. It is effective in treating both primary and secondary MR, as reported in the surgical and interventional literature. Over time, TEER has gained popularity and achieved procedural success in various anatomies. The less invasive nature of TEER, along with its high safety profile and immediate haemodynamic improvement suggest potential benefits in high-risk populations who are not normally included in major ...
Source: EuroIntervention - February 23, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Mony Shuvy Francesco Maisano Source Type: research